<DOC>
	<DOCNO>NCT00228124</DOCNO>
	<brief_summary>The purpose study determine , patient enter National Cancer Institute Canada ( NCIC ) -PR.7 trial intermittent versus continuous androgen ablation , whether rate osteoporosis , fracture , alteration body composition reduce intermittent androgen ablation . There two group patient : 1 . A cross-sectional group 150 patient register PR.7 prior January 1 , 2002 , randomize intermittent androgen suppression ( IAS ) continuous androgen suppression ( CAS ) ( 75 group ) . Patients definite bone metastasis exclude study . Biochemical failure exclude patient . 2 . A longitudinal study 150 newly accrue patient randomize IAS CAS ( 75 group ) . These patient baseline evaluation bone loss body composition , longitudinal monitoring follow-up annual basis patient CAS end “ cycle ” IAS . Patients take bisphosphonates exclude study .</brief_summary>
	<brief_title>PR.7 Companion Trial : Effect Intermittent Versus Continuous Androgen Suppression Bone Loss Body Composition</brief_title>
	<detailed_description>Primary Objectives : 1 . To compare CAS IAS respect bone mineral density ( BMD ) : We determine whether bone loss associate long term CAS reduce IAS evaluation : 1 . BMD , 2. biochemical marker bone formation/resorption , 3. skeletal relevant event ( SRE ) ( defined pathological fracture , symptomatic hypercalcemia hypocalcemia , spinal cord compression , need spinal orthosis vertebral deformity collapse ) . 2 . To compare CAS IAS respect body composition : We determine whether reduction muscle mass increase fat accumulation associate long term CAS reduce IAS . We evaluate : 1. percentage fat body mass , 2. percentage lean body mass 3. body mass index . 3 . To evaluate predictive value germline polymorphism Vitamin D receptor ( VDR ) gene bone loss Eligible Patients PR.7 : 1 . Histologically confirm prostate cancer ( PCa ) 2 . Completed radiotherapy prostatic area 12 month prior randomization 3 . Rising prostate specific antigen ( PSA ) level ( serum PSA &gt; 3 ng/ml ( 3 μg/L ) ) high low level record previously since end radiotherapy ( i.e . high post-radiotherapy nadir ) 4 . No definite evidence distant metastasis ( radiological change compatible non-malignant disease acceptable ) 5 . No prior hormonal therapy exception neo-adjuvant cytoreduction prior radical radiotherapy prostatectomy maximum duration 12 month complete least 12 month prior randomization Evaluation protocol treatment take place ass difference BMD , body composition , biochemical genetic marker bone disease two group .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Histologically confirm PCa Completed radiotherapy prostatic area 12 month prior randomization Rising PSA level ( serum PSA &gt; 3 ng/ml ( 3 μg/L ) ) high low level record previously since end radiotherapy ( i.e . high postradiotherapy nadir ) No definite evidence distant metastasis ( radiological change compatible nonmalignant disease acceptable ) No prior hormonal therapy exception neoadjuvant cytoreduction prior radical radiotherapy prostatectomy maximum duration 12 month complete least 12 month prior randomization . Severe osteoporosis</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>Continuous androgen suppression</keyword>
	<keyword>Intermittent androgen suppression</keyword>
	<keyword>Bone loss</keyword>
	<keyword>Osteoporosis</keyword>
</DOC>